Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,417 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Actinic Keratoses
Interventions: Cryotherapy, 5Fluorouracil; Procedure · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions: Intravenous immunoglobulin, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post-operative Complications, Surgical Site Infection, Surgical Wound Infection
Interventions: Prevena™ Incision Management System (PIMS), Standard-of-care Dressing; Device
Lead sponsor: KCI USA, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Decompensated Heart Failure
Interventions: Loop diuretics (furosemide, torsemide, bumetanide), Ultrafiltration; Drug · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Anesthesia
Interventions: Needle-Free Jet Injection of 1 % lidocaine, traditional needle infiltration of 1% lidocaine; Device · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 1 Day to 3 Months
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Urinary Incontinence
Interventions: APP Co-management, E-consult; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • Lawrence, Kansas

Conditions: Delirium, Sleep
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting
Interventions: Remibrutinib, Ocrelizumab (US); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Head and Neck Carcinoma, Radiation-Induced Dermatitis
Interventions: Dakin's solution, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: San Jose, California • Stanford, California

Conditions: Orthostatic Hypotension, Falls
Interventions: Medication review, Nutrition/Salt intake, Education, Exercise, Drug Recommendations; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pancreatitis
Interventions: Data Management and Monitoring; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2,345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Sclerosing Cholangitis
Interventions: oral vancomycin and oral amoxicillin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 76 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Fragile X Syndrome
Interventions: AFQ056, Placebo, Language Intervention; Drug · Other
Lead sponsor: Elizabeth Berry-Kravis; Other
Eligibility: 32 Months to 6 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 14
States / cities: Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Urinary Tract Infections
Interventions: D-Mannose; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-102; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 16
States / cities: Tucson, Arizona • Loma Linda, California • San Diego, California + 11 more

Conditions: Osteoarthritis
Interventions: GSK3196165, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Miami, Florida • Duncansville, Pennsylvania

Conditions: Diabetic Foot Ulcer, Diabetic Foot
Interventions: Medaxis Debritom+, Sharp Surgical Debridement, Additional Outer Dressing Application, Offloading, Fibracol Wound Dressing; Other
Lead sponsor: Medaxis, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: San Francisco, California • South Miami, Florida • Frederick, Maryland + 3 more

Conditions: Lung Cancer, Metastatic Cancer
Interventions: erlotinib hydrochloride, immunoenzyme technique, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study, stereotactic radiosurgery; Drug · Other · Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: CKD, ESRD
Interventions: Long term hemodialysis catheter; Device
Lead sponsor: Medical Components, Inc dba MedComp; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19
Interventions: Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment; Biological · Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more

Conditions: Systemic Sclerosis, Diffuse Scleroderma
Interventions: Privigen; Biological
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Cognitive Impairment
Interventions: Speed of Processing Training, Transfer Package from CI Therapy; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Gastroesophageal Reflux Disease
Interventions: Study Arm - acid suppression plus feeding bundle, Conventional arm - acid suppression only; Other
Lead sponsor: Sudarshan Jadcherla; Other
Eligibility: 34 Weeks to 60 Weeks
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Vasculitis
Interventions: Avacopan; Drug
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Minneapolis, Minnesota + 7 more

Search by objective public record fields.

Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions

Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics

Needle-Free Lidocaine Injection vs Traditional Local Anesthesia in Infant Lumbar Puncture

Outcomes of Urinary Incontinence Treatment in Primary Care: APP Co-Management and Electronic Consult

Investigation of Sleep in the Intensive Care Unit

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Orthostatic Hypotension Treatment on Rehab Unit

Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies

Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

AFQ056 for Language Learning in Children With FXS

Nutraceutical Efficacy for rUTI

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot

Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases

Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

IVIG Treatment in Systemic Sclerosis

Improving Thinking in Everyday Life: Pilot Study A

Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.